The 2022 Panjiayuan Consensus Conference, held by the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, has introduced pivotal advancements in prostate targeted biopsy (TB) strategies and development, marking a significant leap forward in the diagnosis and management of prostate cancer (PCa). 

Read More